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Abstract
Background: The effect of glycemic control after starting peritoneal dialysis (PD) on the survival of diabetic PD patients has
largely been unexplored, especially in Asian population.
Methods: We conducted a prospective observational study, in which 140 incident PD patients with diabetes were recruited.
Patients were divided into tertiles according to the means of quarterly HbA1C levels measured during the first year after
starting PD. We examined the association between HbA1C and all-cause mortality using Cox proportional hazards models.
Results: The mean age was 58.7 years, 59.3% were male, and the mean follow-up duration was 3.5 years (range 0.4–9.5
years). The mean HbA1C levels were 6.3%, 7.1%, and 8.5% in the 1st, 2nd, and 3rd tertiles, respectively. Compared to the 1st
tertile, the all-cause mortality rates were higher in the 2nd [hazard ratio (HR), 4.16; 95% confidence interval (CI), 0.91–18.94;
p = 0.065] and significantly higher in the 3rd (HR, 13.16; 95% CI, 2.67–64.92; p = 0.002) tertiles (p for trend = 0.005), after
adjusting for confounding factors. Cardiovascular mortality, however, did not differ significantly among the tertiles (p for
trend= 0.682). In contrast, non-cardiovascular deaths, most of which were caused by infection, were more frequent in the
2nd (HR, 7.67; 95% CI, 0.68–86.37; p = 0.099) and the 3rd (HR, 51.24; 95% CI, 3.85–681.35; p = 0.003) tertiles than the 1st tertile
(p for trend= 0.007).
Conclusions: Poor glycemic control is associated with high mortality rates in diabetic PD patients, suggesting that better
glycemic control may improve the outcomes of these patients.
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Introduction
Diabetes mellitus (DM) is the leading cause of end-stage renal
disease (ESRD) worldwide, accounting for more than 40% of
incident dialysis patients in the United States [1]. To delay
diabetic nephropathy from progressing and to improve outcomes
for DM patients, a multidisciplinary approach is currently
recommended, including glycemic control [2].
Accumulating evidences have shown that tight glycemic control
prevents the development and progression of diabetic complica-
tions in both type 1 and type 2 DM patients [3–5]. In addition,
high blood glucose concentrations were found to be associated
with increased incidence of cardiovascular disease in diabetic
patients [6]. Moreover, HbA1C levels were revealed as an
independent risk factor for coronary heart disease in diabetic
patients [7]. Since cardiovascular diseases are the most common
cause of death in DM patients, it has been surmised that strict
glucose control may be favorable to the outcome in these patients.
However, recent several randomized controlled trials have failed
to demonstrate any beneficial effects of strict glycemic control on
the cardiovascular morbidity and mortality in type 2 DM patients
without advanced renal failure [8–10].
While many previous studies have excluded diabetic patients
with advanced renal failure, only a few investigations have
explored the impact of glycemic control on the prognosis of DM
patients on dialysis, with inconsistent results [11–14]. An
American report using a database from a large dialysis
organization showed a significant correlation between the levels
of HbA1C and prognosis in diabetic patients on hemodialysis
(HD) [13], while another recent Canadian study found that higher
blood glucose and HbA1C levels were not associated with
mortality in maintenance HD patients with DM [14]. Different
from HD, peritoneal dialysis (PD) results in a large amount of
glucose load that is continuously absorbed from the dialysate.
Therefore, glycemic control may be more difficult, and the impact
of strict glycemic control on the clinical outcomes may be more
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obvious in diabetic PD patients, but definite evidence is
furthermore lacking in these patients. To date, only one study
has investigated the relationship between glycemic control after
starting PD and the clinical outcomes in type 2 diabetic PD
patients, in which only a few Asians were included [15]. Although
there has been a study conducted in Asian population to show the
association between glycemic control and patient outcomes,
glycemic control before starting dialysis was used as an indicator
of glycemic control [16]. In this study, we tried to determine
whether glycemic control after starting PD was associated with all-
cause and cardiovascular mortality in Asian diabetic PD patients.
Methods
Ethics statement
This study was approved by the Institutional Review Board for
human research at Yonsei University College of Medicine, and all
participants provided their written informed consent prior to study entry.
Study setting and participants
For this prospective observational study, we recruited 145
incident continuous ambulatory PD patients with DM from a
single Korean dialysis center, and followed them at Yonsei
University Health System in Seoul, Korea. Enrollment of patients
was conducted from Jan 2001 until December 2008. The diagnosis
of DM at the initiation of PD was based on the diagnostic criteria of
the American Diabetes Association [17]. We excluded patients who
were younger than 20 years old (n= 1), had a history of malignancy
(n= 1), a history of receiving a kidney transplant (n= 1), or a history
of HD for more than three months (n= 1). Patients who failed to
maintain PD for more than three months were also excluded (n= 1).
Data Collection
To assess glycemic control, monthly preprandial blood glucose
and quarterly HbA1C levels were collected during the first year
after starting PD. However, to exclude the possibility of undue
hyperglycemia, the HbA1C levels were omitted from mean
HbA1C levels when measured during acute illness or when taking
medications such as glucocorticoid that can affect blood glucose
concentrations. Blood glucose concentrations were determined by
the hexokinase-UV method and HbA1C levels were measured by
high-performance liquid chromatography. The mean preprandial
blood glucose and HbA1C values were used for this analysis.
The following demographic and clinical data were collected for
each patient at the beginning of PD: age, gender, height, weight,
body mass index (BMI), primary renal disease, duration of DM,
smoking status, and comorbid conditions including hypertension,
chronic lung disease, chronic liver disease, cardiovascular disease
(CVD), and other serious medical illnesses. CVD included
coronary artery disease, peripheral vascular disease, and cerebro-
vascular disease. The Charlson comorbidity index (CCI) score was
used to quantify comorbid conditions [18]. Information on blood
pressure and antihypertensive medications was collected at 3
months after beginning PD, when the patients’ volume status had
stabilized. The management of hyperglycemia was categorized
into 4 groups; no medication, oral hypoglycemic agents alone,
insulin alone, and combined treatment (oral hypoglycemic agents
and insulin). The following laboratory data were also measured
from blood samples taken 3 months after beginning PD:
hemoglobin, white blood cell count, blood urea nitrogen,
creatinine, albumin, calcium, phosphorus, intact parathyroid
hormone (iPTH), total cholesterol, uric acid, bicarbonate, and
high sensitivity c-reactive protein (hsCRP). Residual GFR was
calculated as the average of urea and creatinine clearance from a
24-hour urine collection. Kt/Vurea was determined from the total
urea nitrogen loss in the spent dialysate using the Watson equation
[19], and normalized protein catabolic rate (nPCR) [20] was
assessed for nutritional status.
Outcomes
Patients were classified into tertile groups, based on their
average HbA1Cs during the first year after beginning PD, and
prospectively followed from enrollment until death, transfer to an
alternative dialysis method, or Dec 2010. Patients who transferred
to HD or transplantation were censored for the patient survival
analysis. The primary and secondary outcomes for all analyses
were all-cause and cardiovascular mortality, respectively.
Statistical analysis
Statistical analysis was performed using SPSS version 13.0
(SPSS, Inc., Chicago, Illinois, USA). Data were basically expressed
as mean6 standard deviation (SD) or percentages. Due to the log-
normal distributions of hsCRP and iPTH, natural log values were
used for analyses. Geometric means for all log-normally
distributed continuous variables were calculated and reported
with geometric SD. Results were analyzed using ANOVA or chi-
square tests for comparisons. Significant differences detected by
ANOVA were further confirmed by the Student’s t-tests with the
Bonferroni corrections. The relationships between HbA1C and
preprandial blood glucose or log-transformed hsCRP (log hsCRP)
levels were determined by Pearson’s correlation analysis. Cox
proportional hazards analysis was performed on variables revealed
to be significant by univariate analysis to define the effect of
HbA1C levels on mortality. A case-mix model was performed after
adjusting for age, gender, year of PD start, CCI score. In the fully-
adjusted model, mean arterial pressure (MAP), serum creatinine,
albumin, and log hsCRP levels were further adjusted in addition to
all variables used in the case-mix model. P-values less than 0.05
were considered statistically significant.
Results
Baseline characteristics and laboratory findings of
patients
Of the 810 patients who began PD between January 2001 and
December 2008, 145 patients had DM. After excluding 5 patients, a
total of 140 patients were finally recruited in this study. The baseline
characteristics of the study patients are shown in Table 1. The mean
age was 58.7 years, 59.3% were male, and the mean follow-up
duration was 3.5 years (range 0.4–9.5 years). The primary renal
diseases were diabetic nephropathy (85.0%), chronic glomerulone-
phritis (7.1%), and hypertensive nephrosclerosis (4.3%) in order.
Hypertension and CVD were accompanied in 139 (99.3%) and 44
(31.4%) patients, respectively. The mean systolic and diastolic blood
pressures were 133.9619.4 and 77.5611.5 mmHg, respectively,
and 75.7% of patients were taking RAS blockades. The frequency
distribution of HbA1C values for all study patients is shown in
Figure 1, and 47.1% of patients were within the recommended
target HbA1C (less than 7%). Hypoglycemia occurred at the
frequency of 1.1 events per 100 patient-year.
During the follow-up, 23 (16.4%) patients died, 28 (20.0%) were
transferred to HD, and 7 (5.0%) received a kidney transplant.
Cardiovascular disease (39.1%) and infection (39.1%) were the
most common causes of death. Among death due to infection, PD-
related infection such as PD peritonitis accounted for only 22.2%
of all infection-related death, while non-PD-related causes,
including pneumonia, wound infection, and necrotizing colitis,
contributed to the majority of infection-related death (77.8%).
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Correlation between preprandial blood glucose and
HbA1C
Pearson’s correlation analysis revealed a significant correlation
between preprandial blood glucose and HbA1C concentrations, as
shown in Figure 2 (r = 0.622, p,0.001). Using a linear regression
model, the following formula was extracted:
HbA1C %ð Þ~preprandial serum glucose mg=dLð Þ|0:016z5:377
On the other hand, there was no significant association between
HbA1C and log hsCRP levels (r = 0.029, p = 0.744).
Comparisons of clinical and biochemical parameters
among patients according to HbA1C levels
To explore whether patients with good and poor glycemic
control had different clinical and biochemical parameters, the
study subjects were divided into tertile groups according to their
mean of HbA1C levels. The mean HbA1C levels in the 1st, 2nd,
and 3rd tertiles were 6.3% (range, 5.2–6.7), 7.1% (6.8–7.5), and
8.5% (7.6–13.3), respectively. The percentage of patients in each
tertile with HbA1C levels within the levels recommended by the
American Diabetes Association [2] were 100%, 42.6%, and 0% in
the 1st, 2nd, and 3rd tertiles, respectively. The proportion of male
patients was significantly higher in the 1st and 2nd tertiles than in
the 3rd tertile (p,0.05). Serum albumin was significantly lower in
Table 1. Comparision of demographic, clinical, and laboratory characteristics in each tertile.
I (5.15–6.7) II (6.8–7.5) III (7.6–13.25) P
n=140 n=46 n=47 n=47
Age, years (SD) 58.7610.6 57.2611.5 59.269.2 59.6611.0 0.493
Male gender 83 (59.3%) 33 (71.7%) 30 (63.8%) 20 (42.6%) 0.012
Follow-up duration, years 3.562.0 3.661.9 3.962.0 3.061.9 0.095
Diabetes as the cause of ESRD 119 (85.0%) 37 (80.4%) 40 (85.1%) 42 (89.4%) 0.105
CVD 44 (31.4%) 18 (39.1%) 10 (21.3%) 16 (34.0%) 0.160
CCI score 5.861.4 5.661.4 5.861.2 6.061.7 0.352
Year of starting PD 0.306
2001,2004 45 (32.1%) 12 (26.1%) 14 (29.8%) 19 (40.4%)
2005,2008 95 (67.9%) 34 (73.9%) 33 (70.2%) 28 (59.6%)
BMI (kg/m2) 23.262.7 23.463.0 23.462.4 22.862.8 0.489
Systolic BP (mmHg) 133.9619.4 134.1619.2 135.2621.2 132.4617.9 0.796
Diastolic BP (mmHg) 77.5611.5 77.8611.0 78.2611.0 76.6612.6 0.778
Methods of glycemic control 0.135
Insulin 55 (39.3%) 17 (37.0%) 18 (38.3%) 20 (42.6%)
Oral hypoglycemic agent 59 (42.1%) 24 (52.2%) 20 (42.6%) 15 (31.9%)
Combined 19 (13.6%) 3 (6.5%) 5 (10.6%) 11 (23.4%)
No control 7 (5.0%) 2 (4.3%) 4 (8.5%) 1 (2.1%)
Hypoglycemic event* 1.1 0.9 1.1 1.2 0.250
Hemoglobin (g/dL) 11.061.7 11.061.8 11.161.8 10.961.5 0.842
HbA1C (%) 7.361.1 6.360.3 7.160.3 8.561.1 ,0.001
Preprandial glucose (mg/dL) 145.3650.3 104.9622.6 136.2616.6 194.0652.2 ,0.001
Creatinine (mg/dL) 6.662.4 6.962.6 6.962.7 6.061.9 0.100
Albumin (g/dL) 3.360.5 3.460.4 3.460.4 3.160.5(I,II) 0.003
Total cholesterol (mg/dL) 184.1644.6 178.7645.6 180.2638.1 193.3649.0 0.220
Bicarbonate (mmol/L) 27.763.1 27.763.0 27.663.2 28.063.3 0.821
Calcium (mg/dL) 8.960.9 8.961.0 9.160.8 8.960.9 0.411
Phosphorus (mg/dL) 4.261.0 4.461.0 4.260.9 4.060.9 0.125
iPTH (pg/mL)# 74.963.5 98.264.1 70.063.5 59.362.9 0.245
hsCRP (mg/L)# 1.5765.38 1.6065.37 1.3165.02 1.8365.85 0.654
Total Kt/Vurea 2.4860.62 2.3760.61 2.5460.68 2.5560.58 0.450
RRF (ml/min/1.73 m2) 4.6263.20 4.5962.49 4.5063.88 4.7663.38 0.953
nPCR (g/kg/day) 0.9760.21 0.9560.21 1.0460.21 0.9460.20 0.120
Data are presented as mean 6 SD or n (%).
#expressed as geometric mean 6 geometric SD. ESRD, end-stage renal disease; CVD, cardiovascular disease; CCI, Charlson comorbidity index; PD, peritoneal dialysis;
BMI, body mass index; BP, blood pressure; iPTH, intact parathyroid hormone; hsCRP, high-sensitivity C-reacitve protein; RRF, residual renal function; nPCR, normalized
protein catabolic rate.
*per 100-patient year.
doi:10.1371/journal.pone.0030072.t001
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the 3rd tertile than the 1st tertile (p,0.05). In contrast, there were
no significant differences among the three tertiles in age,
proportion of diabetes as the cause of ESRD, CCI score, BMI,
systolic and diastolic blood pressure, hemoglobin, creatinine,
calcium, phosphorus, total cholesterol, log-transformed iPTH, and
log hsCRP levels. Residual renal function, Kt/Vurea, and nPCR
were also comparable among the three groups. In addition, there
was no difference in the frequencies of hypoglycemic events
among tertiles (Table 1).
Causes of death among patients according to HbA1C
levels
The causes of death for each tertile are shown in Table 2.
Overall, cardiovascular disease and infection were the most
common causes of death (18.5 per 1000-patient-year for each).
However, while deaths from cardiovascular diseases occurred at
similar frequencies across tertiles, deaths from infection increased
according to increasing HbA1C tertiles. Therefore, compare to the
1st tertile, all-cause mortality increased in the 2nd tertile and even
more increased in the 3rd tertile. While cardiovascular disease was
the most common cause of death in the 1st (12.2 per 1000-patient
year) and 2nd (22.0 per 1000-patient-year) tertiles, infection was the
leading cause of death in the 3rd tertile (42.6 per 1000-patient-year).
Factors influencing all-cause mortality
In univariate Cox proportional hazards analysis, age [hazard
ratio (HR), 1.07 per 1 year; 95% confidence interval (CI), 1.02–
1.13; p= 0.01], CCI score (HR, 1.82 per 1 point; 95% CI, 1.24–
2.67; p,0.01), and log hsCRP (HR, 1.43 per 1 unit; 95% CI,
1.10–1.87; p,0.01) were significantly associated with all-cause
mortality in diabetic PD patients, whereas there were significant
inverse correlations between all-cause mortality and variables such
as MAP (HR, 0.95 per 1 mmHg; 95% CI, 0.92–0.99; p = 0.013)
and serum creatinine [HR, 0.83 per 1 mg/dL; 95% CI, 0.68–
0.99; p = 0.045].
Impact of HbA1C levels on all-cause mortality
Although all-cause mortality in the 3rd tertile group was
significantly higher than in the 1st tertile (HR, 4.18; 95% CI,
1.15–15.21; p = 0.030), higher HbA1C levels were not associated
with all-cause mortality in the unadjusted Cox proportional
hazards analysis (p for trend= 0.089) (Table 3 and Figure 3). Using
case-mix and fully-adjusted models, however, there was a
significant association between the mean HbA1C levels and all-
cause mortality (p for trend, 0.020 and 0.005, respectively). In the
case-mix model, there were 2.22- and 6.08-fold increases in the
risk of all-cause mortality in the 2nd (95% CI, 0.58–8.41; p= 0.243)
and the 3rd tertiles (95% CI, 1.58–23.49; p = 0.009), respectively,
compared to the 1st tertile. The risk of all-cause mortality
increased further in the 2nd (HR, 4.16; 95% CI, 0.91–18.94;
p = 0.065) and 3rd tertiles (HR, 13.16; 95% CI, 2.67–64.92;
p = 0.002) using the fully-adjusted model.
Impact of HbA1C levels on cardiovascular mortality
The risk of cardiovascular mortality was comparable among the
three tertiles in the unadjusted, case-mix, and fully-adjusted
models (p for trend, 0.731, 0.532, and 0.682, respectively) (Table 3
and Figure 3).
Impact of HbA1C on non-cardiovascular mortality
The risk of non-cardiovascular mortality increased in the 2nd
(HR, 4.16; 95% CI, 0.49–35.65; p = 0.194) and 3rd tertiles (HR,
8.31; 95% CI, 1.02–51.57; p = 0.048) compared to the 1st tertile,
but this trend failed to reach statistical significance (p for trend,
0.107). In the case-mix model, there were 3.01- and 13.03-fold
increases in the risk of non-cardiovascular mortality in the 2nd
(95% CI, 0.34–26.78; p = 0.323) and the 3rd tertiles (95% CI,
1.47–85.34; p = 0.021), respectively, compared to the 1st tertile (p
for trend= 0.029). The risk of non-cardiovascular mortality
Figure 2. Bivariate correlation analysis between HbA1C and
preprandial glucose (Glucose AC).
doi:10.1371/journal.pone.0030072.g002
Table 2. Differences in the cause of death among tertiles.
Cause of death I II III Total
Cardiovascular disease 12.2 22.0 21.3 18.5
Infection 0 16.5 42.6 18.5
Other (Malignancy,
Bleeding)
6.1 11.0 7.1 8.2
All-cause 18.3 49.5 71.0 45.2
per 1000-patient-year.
doi:10.1371/journal.pone.0030072.t002
Figure 1. The frequency distribution of HbA1C values for all
study patients.
doi:10.1371/journal.pone.0030072.g001
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significantly increased further in the 2nd (HR, 7.67; 95% CI, 0.68–
86.37; p = 0.099) and 3rd tertiles (HR, 51.24; 95% CI, 3.85–
340.35; p = 0.003) using the fully-adjusted model (p for
trend= 0.007), as shown in Table 3 and Figure 3.
Impact of HbA1C on clinical outcomes in diabetic PD
patients, whose etiology of ESRD was diabetic
nephropathy
To elucidate whether the impact of glycemic control on clinical
outcomes was comparable in diabetic PD patients whose etiology
of ESRD was diabetic nephropathy, we performed additional
analysis with the data of these patients (n = 119). The risk of all-
cause mortality was not significantly increased in the 2nd (HR,
1.40; 95% CI, 0.35–5.60; p= 0.638) and 3rd tertiles (HR, 3.69;
95% CI, 0.99–13.70; p = 0.051) compared to the 1st tertile in the
unadjusted model (p for trend= 0.065). In the case-mix model,
however, there were 1.2- and 4.68-fold increases in the risk of all-
cause mortality in the 2nd (95% CI, 0.29–5.05; p = 0.328) and 3rd
tertiles (95% CI, 1.19–18.44; p = 0.028), respectively, compared to
the 1st tertile (p for trend= 0.023). The risk of all-cause mortality
increased further in the 2nd (HR, 3.30; 95% CI, 0.57–19.28;
p = 0.185) and 3rd tertiles (HR, 12.71; 95% CI, 2.23–42.39;
p = 0.004) using the fully-adjusted model (p for trend= 0.010).
Meanwhile, there was a significant increase in the risk of non-
cardiovascular mortality in the 2nd (HR, 4.62; 95% CI, 0.33–
44.42; p = 0.255) and 3rd tertiles (HR, 33.92; 95% CI, 2.80–
120.22; p = 0.003) relative to the 1st tertile using the fully-adjusted
model (p for trend= 0.006), while the risk of cardiovascular
mortality was comparable among the three tertiles in the
unadjusted, case-mix, and fully-adjusted models (p for trend,
0.898, 0.920, and 0.498, respectively) (Table 4).
Discussion
In this prospective observational study on 140 incident diabetic
PD patients from a single center, we found that poor glycemic
control was associated with increased risk of mortality in diabetic
PD patients, after adjusting for confounding factors. However,
there were no differences in cardiovascular mortality rates among
patients with different levels of glycemic control. These findings
suggest that diabetic patients on PD could benefit from strict
glycemic control, even if such control may not decrease
cardiovascular mortality.
Tight glycemic control has been demonstrated to prevent the
development and progression of microvascular complications and
to be associated with reduced risk of coronary heart disease in
diabetic patients [3–5]. In addition, previous studies have shown
that high blood glucose concentrations are associated with
increased incidence of cardiovascular diseases in patients with
DM [6,7]. Based on these findings, it has been supposed that strict
glucose control could exert a beneficial impact on the survival and
cardiovascular outcome in diabetic patients, drawing up current
guidelines of a target HbA1C level of 7.0% or less for most DM
patients. Against these expectations, however, several recent
studies showed that there was no beneficial effect of tight glycemic
control on the cardiovascular morbidity and mortality in type 2
DM patients without advanced renal failure [8–10].
Findings regarding the impact of glycemic control on the
outcomes of DM patients on dialysis have also been inconsistent.
An analysis of 23,618 American diabetic HD patients showed that
the adjusted risk for all-cause mortality in patients with HbA1C
$10.0% was 1.41-higher than patients with HbA1C in the 5–6%
range [13]. Most previous studies including East Asian diabetic
patients on HD also found that poor glycemic control was
associated with reduced surivival, which agrees with the results of
our study [11,21]. In contrast, a recent study by Shurraw et al [14]
showed that higher blood glucose and HbA1C levels were not
associated with mortality in 1,484 incident HD patients in
Canada. These conflicitng results may be attributed to the
differences in ethnicity, body size, the duration of dialysis, and
the definition of good glycemic control.
Meanwhile, there has been only one study conducted among
PD patients, and it has revealed that poor glycemic control was
associated with poor survival in diabetic PD patients [15].
However, few Asian patients were included in that study, and
the impact of glycemic control on patient outcomes among Asian
diabetic PD patients is still unclear. Although another report by
Wu et al [16], which was conducted among Asian PD patients,
revealed that glycemic control before starting dialysis was a
predictor of survival for type 2 diabetic patients on PD, the
importance of glycemic control after starting dialysis was not
evaluated. Since PD fluid contains extremely high concentrations
of glucose, we hypothesized that the glycemic control in PD
patients would be different from the predialysis state. Therefore,
we determined glycemic control by using average HbA1C levels
during the 1st year after beginning PD, which were supposed to
better reflect overall serum glucose concentrations. To exclude the
possibility of improper hyperglycemia, moreover, the HbA1C
levels around the time of acute illness or when taking medications
that could affect serum glucose concentrations were omitted from
the mean HbA1C levels.
In this study, poor glycemic control was associated with
deleterious outcomes but not cardiovascular mortality which is
the most common cause of death in ESRD patients undergoing
dialysis. Consistent with these results, most previous studies have
failed to demonstrate that good glycemic control improves
cardiovascular survival in patients with long duration of DM [8–
10]. Since most diabetic ESRD patients already have advanced
microvascular and macrovascular complications, there might be a
‘‘point of no return’’, after which patient outcomes are not affected
Table 3. Risk of all-cause, cardiovascular, and non-
cardiovascular mortality among tertiles (n = 140).
All-cause Cardiovascular
Non-
cardiovascular
Model HR (95% CI) HR (95% CI) HR (95% CI)
Unadjusted P for trends 0.089 P for trends 0.731 P for trends 0.107
Tertile I 1.00 1.00 1.00
Tertile II 2.55 (0.69–9.41) 1.74 (0.32–9.54) 4.16 (0.49–35.65)
Tertile III 4.18 (1.15–15.21) 2.02 (0.33–12.17) 8.31 (1.02–51.57)
Case-mix P for trends 0.020 P for trends 0.532 P for trends 0.029
Tertile I 1.00 1.00 1.00
Tertile II 2.22 (0.58–8.41) 1.76 (0.30–10.21) 3.01 (0.34–26.78)
Tertile III 6.08 (1.58–23.49) 3.09 (0.43–22.28) 13.03 (1.47–85.34)
Fully-adjusted P for trends 0.005 P for trends 0.682 P for trends 0.007
Tertile I 1.00 1.00 1.00
Tertile II 4.16 (0.91–18.94) 2.80 (0.28–28.40) 7.67 (0.68–86.37)
Tertile III 13.16 (2.67–64.92) 2.46 (0.15–39.67) 51.24 (3.85–340.35)
Case-mix model is adjusted for age, gender, year of PD start, Charlson
comorbidity index score. Fully-adjusted model is adjusted for mean arterial
pressure, albumin, serum creatinine, and log-transformed hsCRP, in addition to
all variables which were used in case-mix model.
doi:10.1371/journal.pone.0030072.t003
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by strict glycemic control. Is it also relevant for diabetic ESRD
patients whose primary renal diagnosis is not diabetic nephrop-
athy? To answer this issue, we performed an additional subgroup
analysis in patients whose primary renal disease was diabetic
nephropathy. In result, the all-cause and non-cardiovascular
mortality was also significantly higher in the 3rd tertile group
compared to the 1st tertile group, whereas the risk of cardiovas-
cular mortality was not different among groups, which were
similar to the results with all diabetic PD patients. Therefore, it is
surmised that ‘‘point of no return’’ theory can be applied at least to
PD patients in whom the etiology of ESRD was diabetic
nephropathy. Meanwhile, a previous American report [13]
observed a significantly higher cardiovascular mortality in patients
with HbA1C $10.0%, while the rates were comparable among
patients with HbA1C levels between 5.0% and 10.0%, suggesting
that only extremely uncontrolled hyperglycemia may affect
cardiovascular outcomes. Only 4 patients (2.8%) in our study
sample had mean HbA1C levels greater than 10.0%, and
therefore this effect might not be reflected in our study. There is
also another possibility that ‘‘survival bias’’ could be involved in
Figure 3. Comparison of cumulative survival among tertiles, plotted by Cox proportional hazards analysis. (A–B) Comparison of all-
cause mortality among tertiles in unadjusted (A) and fully-adjusted model (B). (C–D) Comparison of cardiovascular mortality among tertiles in
unadjusted (C) and fully-adjusted model (D). (E–F) Comparison of non-cardiovascular mortality among tertiles in unadjusted (E) and fully-adjusted
model (F).
doi:10.1371/journal.pone.0030072.g003
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the results of cardiovascular mortality. In our study subjects, CVD
was less in tertile II (21.3%), as compared with tertile I (39.1%) and
tertile III (34.0%). One explanation to this observation is that
patients with moderate glycemic control died of cardiovascular
events even before starting PD and reaching at poorer glycemic
states, and those who have reached to the 3rd tertile survived from
any cardiovascular events.
This study revealed that patients with poor glycemic control had
significantly higher non-cardiovascular mortality, mainly due to
infection. Similarly, a Taiwanese study [16] and another Korean
study on diabetic PD patients [22] also found that the proportion
of mortality from infection was high and comparable to that from
cardiovascular diseases in their subjects, which raises several
questions. Why is there a difference in the proportion of mortality
from infection between diabetic HD and PD patients? Why
infection-related mortality is influenced by the degree of glycemic
control? While the answers are not clear, mounting evidence has
shown that diabetic PD patients may be more vulnerable to
infections. Frequently exchanging PD fluid could eliminate or
dilute phagocytes and immunoglobulins normally present in the
peritoneal cavity. In fact, the amount of removed immunoglobulin
G and C3 through PD is reported to be significantly greater in
DM than non-diabetic patients [23]. Moreover, hypertonic
glucose solution used for PD could make patients susceptible to
infection, especially in diabetic patients. It is well known that 60 to
80% of glucose in dialysate is systemically absorbed by diffusion
and lymphatic absorption during a 6-hour dwell, which makes
strict glycemic control more difficult in PD patients. These local
and systemic hyperglycemic conditions have been suggested to be
able to modify cytokine production and phagocytotic activity of
immune cells by several mechansims, including hyperosmotic
stress [24]. Furthermore, the production of advanced glycation
endproducts can increase under hyperglycemic conditions,
resulting in increased interaction between advanced glycation
endproducts and their receptors, which can in turn increase
inflammatory response [25].
Several shortcomings of this study should be discussed. First, as
a single center study, it is subject to the biases inherent to this study
design. In addition, 145 patients out of the total incident PD
patients (n = 810) had diabetes, which corresponds to only 18% of
incident PD patients. Considering the fact that 35 to 40% of
incident ESRD patients in Korea from 2001 to 2009 had diabetes
[26], we could not completely affirm that there was no selection
bias even though it was not intentional. We surmise that the
discrepancy in the proportion of DM patients between incident
HD and PD patients in our institute may be partially attributed to
our physician’s tendency to hesitate to perform PD in DM
patients, especially in whom predialysis blood glucose control was
not appropriate. In fact, only 2.8% of this study subjects had mean
HbA1C greater than 10.0%, which was much lower than 6.6% of
enrolled patients in an American report [15]. Second, besides
serum glucose and HbA1C levels, laboratory values at 3 months
after starting PD were used for analyses in most cases. Therefore,
the changes of confounding factors during the follow-up were not
reflected. Third, diabetic ESRD patients, whose cause of ESRD
was not diabetic nephropathy, could have different response to
poor glycemic control. However, due to a small number of these
patients (n = 21), subgroup analysis was not able to be performed
for this issue. Lastly, there are some limitations for using HbA1C
levels as a surrogate marker of glycemic control in dialysis patients.
However, tests for better surrogate markers such as glycoalbumin
are not widely performed and have been available in our institute
only after 2009.
In conclusion, this study demonstrated that poor glycemic
control was associated with higher all-cause mortality, mainly non-
cardiovascular mortality represented by infection-related deaths,
in diabetic PD patients. These findings suggest that better glycemic
control may improve the outcome of these patients. Clinical trials
are needed to better examine the impact of strict glycemic control
on survival in diabetic PD patients.
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